Lee HL, Kim JT, Lee JS, et al. - In mild-to-moderate acute ischemic stroke, the effectiveness of dual antiplatelet therapy (DAPT) with clopidogrel-aspirin vs aspirin monotherapy (AM) was investigated, with consideration given to the risk of recurrent stroke using the Stroke Prognosis Instrument II (SPI-II) score. From a prospective, nationwide, multicenter stroke registry database, they retrospectively analyzed data of 15,430 patients (age, 66±13 years; men, 62.0%); of these, 45.1% (n = 6,960) received DAPT and 54.9% (n = 8,470) received AM. In mild-to-moderate acute noncardioembolic ischemic stroke patients, outcomes suggested reduced 3-month vascular events in correlation with providing treatment with clopidogrel-aspirin vs AM. The high-risk subgroup by SPI-II risk scores exhibited larger degrees of the effects of DAPT with clopidogrel-aspirin.